233 related articles for article (PubMed ID: 38117484)
21. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant
Mazor T; Chesnelong C; Pankov A; Jalbert LE; Hong C; Hayes J; Smirnov IV; Marshall R; Souza CF; Shen Y; Viswanath P; Noushmehr H; Ronen SM; Jones SJM; Marra MA; Cairncross JG; Perry A; Nelson SJ; Chang SM; Bollen AW; Molinaro AM; Bengtsson H; Olshen AB; Weiss S; Phillips JJ; Luchman HA; Costello JF
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10743-10748. PubMed ID: 28916733
[No Abstract] [Full Text] [Related]
22. Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging.
Cluceru J; Interian Y; Phillips JJ; Molinaro AM; Luks TL; Alcaide-Leon P; Olson MP; Nair D; LaFontaine M; Shai A; Chunduru P; Pedoia V; Villanueva-Meyer JE; Chang SM; Lupo JM
Neuro Oncol; 2022 Apr; 24(4):639-652. PubMed ID: 34653254
[TBL] [Abstract][Full Text] [Related]
23. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Turcan S; Rohle D; Goenka A; Walsh LA; Fang F; Yilmaz E; Campos C; Fabius AW; Lu C; Ward PS; Thompson CB; Kaufman A; Guryanova O; Levine R; Heguy A; Viale A; Morris LG; Huse JT; Mellinghoff IK; Chan TA
Nature; 2012 Feb; 483(7390):479-83. PubMed ID: 22343889
[TBL] [Abstract][Full Text] [Related]
24. Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status.
Bader JM; Deigendesch N; Misch M; Mann M; Koch A; Meissner F
Cell Rep Med; 2023 Jan; 4(1):100877. PubMed ID: 36584682
[TBL] [Abstract][Full Text] [Related]
25. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
Friedrich M; Hahn M; Michel J; Sankowski R; Kilian M; Kehl N; Günter M; Bunse T; Pusch S; von Deimling A; Wick W; Autenrieth SE; Prinz M; Platten M; Bunse L
Neuro Oncol; 2023 Feb; 25(2):263-276. PubMed ID: 35609569
[TBL] [Abstract][Full Text] [Related]
26. Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma.
Li M; Ren X; Chen X; Wang J; Shen S; Jiang H; Yang C; Zhao X; Zhu Q; Cui Y; Lin S
Eur Radiol; 2022 Jun; 32(6):3869-3879. PubMed ID: 35079884
[TBL] [Abstract][Full Text] [Related]
27. Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.
Back M; Jayamanne D; Brazier D; Newey A; Bailey D; Schembri G; Hsiao E; Khasraw M; Wong M; Kastelan M; Brown C; Wheeler H
Strahlenther Onkol; 2020 Jan; 196(1):31-39. PubMed ID: 31028406
[TBL] [Abstract][Full Text] [Related]
28. Reclassification of Mongolian Diffuse Gliomas According to the Revised 2016 World Health Organization Central Nervous System Tumor Classification.
Ochirjav E; Enkhbat B; Baldandorj T; Choe G
J Pathol Transl Med; 2019 Sep; 53(5):298-307. PubMed ID: 31370384
[TBL] [Abstract][Full Text] [Related]
29. Radiomic features from dynamic susceptibility contrast perfusion-weighted imaging improve the three-class prediction of molecular subtypes in patients with adult diffuse gliomas.
Pei D; Guan F; Hong X; Liu Z; Wang W; Qiu Y; Duan W; Wang M; Sun C; Wang W; Wang X; Guo Y; Wang Z; Liu Z; Xing A; Guo Z; Luo L; Liu X; Cheng J; Zhang B; Zhang Z; Yan J
Eur Radiol; 2023 May; 33(5):3455-3466. PubMed ID: 36853347
[TBL] [Abstract][Full Text] [Related]
30. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival.
Leu S; von Felten S; Frank S; Vassella E; Vajtai I; Taylor E; Schulz M; Hutter G; Hench J; Schucht P; Boulay JL; Mariani L
Neuro Oncol; 2013 Apr; 15(4):469-79. PubMed ID: 23408861
[TBL] [Abstract][Full Text] [Related]
31. Metabolomic Profiles of Human Glioma Inform Patient Survival.
Scott AJ; Correa LO; Edwards DM; Sun Y; Ravikumar V; Andren AC; Zhang L; Srinivasan S; Jairath N; Verbal K; Muraszko K; Sagher O; Carty SA; Hervey-Jumper S; Orringer D; Kim MM; Junck L; Umemura Y; Leung D; Venneti S; Camelo-Piragua S; Lawrence TS; Ippolito JE; Al-Holou WN; Chinnaiyan P; Heth J; Rao A; Lyssiotis CA; Wahl DR
Antioxid Redox Signal; 2023 Nov; 39(13-15):942-956. PubMed ID: 36852494
[No Abstract] [Full Text] [Related]
32. Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.
Kros JM; Rushing E; Uwimana AL; Hernández-Laín A; Michotte A; Al-Hussaini M; Bielle F; Mawrin C; Marucci G; Tesileanu CMS; Stupp R; Baumert B; van den Bent M; French PJ; Gorlia T
Neuro Oncol; 2023 Aug; 25(8):1443-1449. PubMed ID: 36571817
[TBL] [Abstract][Full Text] [Related]
33. A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence.
de Souza CF; Sabedot TS; Malta TM; Stetson L; Morozova O; Sokolov A; Laird PW; Wiznerowicz M; Iavarone A; Snyder J; deCarvalho A; Sanborn Z; McDonald KL; Friedman WA; Tirapelli D; Poisson L; Mikkelsen T; Carlotti CG; Kalkanis S; Zenklusen J; Salama SR; Barnholtz-Sloan JS; Noushmehr H
Cell Rep; 2018 Apr; 23(2):637-651. PubMed ID: 29642018
[TBL] [Abstract][Full Text] [Related]
34. Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas.
Cai J; Zhu P; Zhang C; Li Q; Wang Z; Li G; Wang G; Yang P; Li J; Han B; Jiang C; Sun Y; Jiang T
Oncotarget; 2016 Mar; 7(13):16384-95. PubMed ID: 26918938
[TBL] [Abstract][Full Text] [Related]
35. 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas.
Viswanath P; Radoul M; Izquierdo-Garcia JL; Ong WQ; Luchman HA; Cairncross JG; Huang B; Pieper RO; Phillips JJ; Ronen SM
Cancer Res; 2018 May; 78(9):2290-2304. PubMed ID: 29358170
[TBL] [Abstract][Full Text] [Related]
36. Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in isocitrate dehydrogenase mutant glioma.
Mamatjan Y; Voisin MR; Nassiri F; Moraes FY; Bunda S; So J; Salih M; Shirahata M; Ono T; Shimizu H; Schrimpf D; von Deimling A; Aldape KD; Zadeh G
Neuro Oncol; 2023 Nov; 25(11):2028-2041. PubMed ID: 37474126
[TBL] [Abstract][Full Text] [Related]
37. Telomerase reverse transcriptase promoter mutation and histologic grade in IDH wild-type histological lower-grade gliomas: The value of perfusion-weighted image, diffusion-weighted image, and
Ikeda S; Sakata A; Fushimi Y; Okuchi S; Arakawa Y; Makino Y; Mineharu Y; Nakajima S; Hinoda T; Yoshida K; Miyamoto S; Nakamoto Y
Eur J Radiol; 2023 Feb; 159():110658. PubMed ID: 36571926
[TBL] [Abstract][Full Text] [Related]
38. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
[TBL] [Abstract][Full Text] [Related]
39. Radiomic study on preoperative multi-modal magnetic resonance images identifies IDH-mutant TERT promoter-mutant gliomas.
Wang H; Zhang S; Xing X; Yue Q; Feng W; Chen S; Zhang J; Xie D; Chen N; Liu Y
Cancer Med; 2023 Feb; 12(3):2524-2537. PubMed ID: 36176070
[TBL] [Abstract][Full Text] [Related]
40. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]